DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

What's the purpose of the trial?

Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20.

Trial status

Accepting patients

Phase
Phase 3
Enrollment
1100
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There are 746 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

No Intervention

Accepting patients

Lenalidomide

Accepting patients

Lenalidomide + Daratumumab

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.